Insulet Corporation

PODD

US45784P1012

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-16 pm EST			5-day change	1st Jan Change
287.70 ^USD	+0.42%		-0.46%	+1.22%

Jan. 16	Goldman Sachs Adjusts Price Target on Insulet to $363 From $365, Maintains Buy Rating	MT
Jan. 13	Insulet Corporation Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 11:15 AM

Insulet Wins FDA Clearance for Updated Omnipod 5 Algorithm

Published on 12/04/2025 at 08:22 am EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Insulet Corporation

Jan. 16	Goldman Sachs Adjusts Price Target on Insulet to $363 From $365, Maintains Buy Rating	MT
Jan. 13	Insulet Corporation Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 11:15 AM
Jan. 12	Insulet Shares Fall After Barclays Downgrade	MT
Jan. 12	Barclays Downgrades Insulet to Underweight From Equal Weight, Adjusts Price Target to $274 From $316	MT
Jan. 09	Bernstein Adjusts Price Target on Insulet to $380 From $410, Maintains Outperform Rating	MT
Jan. 09	Goldman Sachs Adjusts Price Target on Insulet to $365 From $388, Maintains Buy Rating	MT
Dec. 18	Truist Securities Lowers Price Target on Insulet to $390 From $412, Maintains Buy Rating	MT
Dec. 17	Canaccord Genuity Adjusts Price Target on Insulet to $450 From $432, Maintains Buy Rating	MT
Dec. 16	Insulet Insider Sold Shares Worth $542,510, According to a Recent SEC Filing	MT
Dec. 16	Evercore ISI Initiates Coverage on Insulet With Outperform Rating, $370 Price Target	MT
Dec. 15	Insulet Corporation Expands Omnipod®? U.S. Recycling Program, Diverting Millions of Pods from Landfills and Creating A More Sustainable Future	CI
Dec. 08	Insulet Insider Bought Shares Worth $299,884, According to a Recent SEC Filing	MT
Dec. 04	Insulet announces FDA 510(k) clearance of Omnipod 5 algorithm enhancements	RE
Dec. 04	Insulet Wins FDA Clearance for Updated Omnipod 5 Algorithm	MT
Dec. 04	Insulet Corporation Announces FDA 510(k) Clearance of Omnipod® 5 Algorithm Enhancements That Redefine Insulin Delivery and Simplify the Pod Experience	CI
Nov. 21	Truist Raises Price Target on Insulet to $412 From $390, Keeps Buy Rating	MT
Nov. 21	RBC Raises Price Target on Insulet to $380 From $370, Keeps Outperform Rating	MT
Nov. 21	BTIG Adjusts Price Target on Insulet to $380 From $370, Maintains Buy Rating	MT
Nov. 21	Raymond James Adjusts Price Target on Insulet to $385 From $366, Maintains Outperform Rating	MT
Nov. 21	Leerink Partners Adjusts Price Target on Insulet to $386 From $385, Maintains Outperform Rating	MT
Nov. 20	Insulet Corporation - Analyst/Investor Day
Nov. 20	Insulet projects revenue CAGR of 20% for 2025-2028	RE
Nov. 19	Insulet Shares Rise After UBS Upgrade	MT
Nov. 19	UBS Upgrades Insulet to Buy From Neutral	MT
Nov. 07	Bernstein Adjusts Insulet Price Target to $410 From $400	MT

Insulet Corporation specializes in the design, manufacture and marketing of medical devices intended to improve the lives of people with insulin-dependent diabetes. In addition, the group offers non-insulin subcutaneous drug delivery systems used in several therapeutic areas. Net sales break down by family of products as follows: - Insulin pump therapy systems (98.1%): continuous insulin management and delivery systems (Omnipod® and Omnipod DASH® brands) and automated insulin administration systems (Omnipod® 5 brand); - non-insulin drug administration systems (1.9%): in particular pre-filled syringes for the Neulasta® Onpro® kit (intended for the treatment of neutropenia in patients treated with chemotherapy). At the end of 2024, the group had 2 production sites located in the United States and in China. The United States accounts for 74.7% of net sales.

Employees

3,900

Sector

Medical Equipment, Supplies & Distribution

Calendar

Feb. 17 - Q4 2025 Earnings Release

More about the company